# CRISPR Brief — Buyer Preview **What you'd actually receive, twice a month** | Sample deliverable v1 --- ## The Problem This Solves You spend 2–4 hours/week screening bioRxiv, FDA filings, and company press releases. Half of it is noise. The other half you miss because you're screening deal flow. CRISPR Brief gives you three things per issue, every two weeks: 1. **The one bioRxiv paper that actually matters** — with impact score, competitive context, and what scouts watch for 2. **The one FDA event worth tracking** — not just "IND cleared" but where it fits in the landscape 3. **The one pipeline move that changes diligence** — framed for scouts, not for lay readers No sponsored content. No opinions. Sourced, citable analysis from a former industry research scientist. --- ## This Issue (Issue Zero) — What's Inside ### Section 1 — bioRxiv Watch **Paper:** Prime editing achieves therapeutic hemoglobin F reactivation in sickle cell disease **Impact Score:** 8.4 / 10 **TL;DR:** Prime editors hit 89% HbF reactivation in a mouse model with no detectable off-target edits at top 50 predicted sites. First prime editing approach to match base editor efficacy in sickle cell — with a better safety profile. **Why scouts care:** Sickle cell space is crowded (Vertex/CRISPR's Casgevy approved, Bluebird's lovo-cel in BLA review, 6+ base editor programs active). The moat is shifting from "can we edit?" to "can we edit without genotoxicity?" Prime editing's precision — exact HbF-correcting edit without double-strand breaks — addresses exactly that risk. **Key datapoint:** 89% HbF reactivation in vivo. Casgevy Phase 3 showed ~80% at 12 months. Comparable efficacy signal, potentially superior safety — in a preclinical model. **One honest concern:** Mouse model only. Translation to human HSCs and durability beyond 16 weeks untested. --- ### Section 2 — FDA Filing Tracker **Filing:** Verve Therapeutics — VERVE-101 IND application **Indication:** Heterozygous familial hypercholesterolemia (HeFH) **Event:** IND clearance — proceed to Phase 1b (April 2026) **What scouts care:** VERVE-101 is an in vivo base editor targeting PCSK9 in the liver — one shot, permanent knock-down. First in vivo base editor to enter the clinic for a cardiometabolic indication. PCSK9 space getting crowded (siRNA drugs approved, olpasiran in Phase 3). Competitive differentiation depends on Phase 1 safety profile holding. **What to watch:** Phase 1b dose-escalation data, expected H2 2026. Primary: safety/tolerability. Secondary: LDL-C reduction at 6 months. --- ### Section 3 — Pipeline Mover **Company:** Beam Therapeutics **Event:** Manufacturing partnership with NIH for GMP-grade base editor manufacturing **Strategic relevance:** High **What scouts care:** Beam's core challenge has been manufacturing scale. NIH partnership signals a viable path to clinical-grade supply. Removes a key diligence question: "Can they manufacture at scale?" — partially, with NIH support. --- ### Section 4 — Meta **Issue cadence:** Biweekly — every other Thursday **Pricing:** Free for first 200 subscribers. $10/month after (early-bird rate — locked for life). $12/month after launch. **Next issue:** May 7, 2026 --- ## What Makes This Different From Other Biotech Newsletters | | CRISPR Brief | Typical biotech newsletter | |---|---|---| | **bioRxiv coverage** | 1 paper/issue — the one that actually matters | 5–10 papers — dump of abstracts | | **Framing** | Scientist's read: competitive context, scouts' watch-outs | Summary paragraph | | **FDA coverage** | Context + competitive significance + what to watch | "IND cleared" bullet | | **Pipeline moves** | Diligence framing — what this removes from your checklist | "Company X did Y" | | **Sponsored content** | None | Often | --- ## Subscribe **Early-bird price:** $10/month — locked for life for first 200 paid subscribers. Free Issue Zero is what you just read above. Paid subscribers get every other Thursday issue + archive access. 👉 **[Subscribe at crispr-brief.html](https://store-v2-khaki.vercel.app/crispr-brief.html#subscribe)** --- *CRISPR Brief is written by a former industry research scientist. Analysis based on publicly available data. This is a sample issue — not investment advice.*